Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
skin and connective tissue diseases | D017437 |
Brand Name | Status | Last Update |
---|---|---|
aromasin | New Drug Application | 2023-09-08 |
exemestane | ANDA | 2023-09-19 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
breast neoplasms | EFO_0003869 | D001943 | C50 |
Code | Description |
---|---|
S0156 | Exemestane, 25 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 30 | 127 | 64 | 9 | 52 | 268 |
Triple negative breast neoplasms | D064726 | — | — | 1 | 7 | 3 | 1 | — | 12 |
Neoplasms | D009369 | — | C80 | 5 | 4 | — | 1 | 1 | 11 |
Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | 1 | 1 | 3 | 5 |
Arthralgia | D018771 | HP_0002829 | M25.5 | — | — | — | 1 | 3 | 4 |
Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | — | 1 | 1 | 1 | 4 |
Osteoporotic fractures | D058866 | — | — | — | — | — | 1 | — | 1 |
Sexuality | D019529 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Male breast neoplasms | D018567 | — | — | 2 | 3 | 2 | — | 2 | 9 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | 1 | — | — | 2 |
Fatigue | D005221 | HP_0012378 | R53.83 | — | — | 1 | — | 1 | 2 |
Sleep wake disorders | D012893 | — | G47 | — | — | 1 | — | 1 | 2 |
Progression-free survival | D000077982 | — | — | — | — | 1 | — | — | 1 |
Ductal carcinoma breast | D018270 | — | — | — | — | 1 | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 2 | 1 | — | — | — | 3 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 1 | — | — | — | 2 |
Breast diseases | D001941 | — | N60-N65 | — | 2 | — | — | — | 2 |
Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
Menopause | D008593 | EFO_0003922 | N95 | — | 1 | — | — | — | 1 |
Radiosurgery | D016634 | — | — | — | 1 | — | — | — | 1 |
Bone neoplasms | D001859 | EFO_0003820 | D16 | — | 1 | — | — | — | 1 |
Hyperplasia | D006965 | EFO_0000536 | — | — | 1 | — | — | — | 1 |
Phenylketonurias | D010661 | — | E70.0 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | — | — | — | — | 1 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 2 | 2 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
Postmenopause | D017698 | — | — | — | — | — | — | 1 | 1 |
Pregnancy rate | D018873 | — | — | — | — | — | — | 1 | 1 |
Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Nutrition disorders | D009748 | EFO_0001069 | — | — | — | — | — | 1 | 1 |
Periodontal diseases | D010510 | — | K05.6 | — | — | — | — | 1 | 1 |
Xerostomia | D014987 | — | K11.7 | — | — | — | — | 1 | 1 |
Hot flashes | D019584 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Exemestane |
INN | exemestane |
Description | Exemestane is a 17-oxo steroid that is androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group. A selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer. It has a role as an EC 1.14.14.14 (aromatase) inhibitor, an antineoplastic agent, an environmental contaminant and a xenobiotic. It is a 17-oxo steroid and a 3-oxo-Delta(1),Delta(4)-steroid. It derives from a hydride of an androstane. |
Classification | Small molecule |
Drug class | antineoplastics (aromatase inhibitors) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12 |
PDB | — |
CAS-ID | 107868-30-4 |
RxCUI | — |
ChEMBL ID | CHEMBL1200374 |
ChEBI ID | 4953 |
PubChem CID | 60198 |
DrugBank | DB00990 |
UNII ID | NY22HMQ4BX (ChemIDplus, GSRS) |